Eli Lilly Stock Forecast 2025 is viewed with high expectations until 2025. The organization has shown strong growth through its weight reduction and diabetes medicines, such as Zepbound and Mounjaro. For 2025, revenue is forecast to accelerate from $58 billion to $61 billion, representing a 32% increase. Experts believe the stock price could reach $1,000 to $1,250. The expansion of the organization and a pipeline of new drugs, such as orforglipron, also provide positive signals for the future.
About the Company
Eli Lilly (LLY) is a driving drug organization with a solid presence in areas such as diabetes, disease, and nervous system science. Investigators are bullish when talking about the 2025 stock estimate, as the organization’s imaginative medicine pipeline and solid financial development assumptions are high. Sharp income development is expected from blockbuster drugs such as Monjaro and Alzheimer’s treatment. Market patterns and medical services requests are also in favor of the stock. However, it is important to consider macroeconomic elements and service dangers as well. This could be a promising choice for long-haul financial backers.
Eli Lilly Stock Business Overview
Eli Lilly Company (LLY) is a driving organization that works in parts such as diabetes, oncology, and nervous system science. Its stock shows solid execution due to ongoing development and blockbuster drugs such as Monjaro and Zepbound. Examiners believe Eli Lilly stock will further develop due to request and pipeline drugs. There is a bullish standpoint for 2025 and beyond, but momentary unpredictability could occur due to high valuations sharp. It is considered a promising stock for long-haul financial backers.
| Metric | Details |
| Founded | 1876 |
| Headquarters | Indianapolis, Indiana. |
| Industry | Eli Lilly Inc |
| Founder | Colonel Eli Lilly |
| Market Focus | Stock Price Target |
| Key Partner | No Partner |
| Employees | 43,000 |
| Stock Symbol | LLY |
Fundamentals of Eli Lilly
Eli Lilly Stock Forecast 2025 generally relies upon major areas of strength for its new medications, particularly in the diabetes and oncology areas. If the organization takes its advancements to fruitful market reception, stock esteem is expected to develop. Financial well-being is also good, and Income development is stable. Market patterns and service changes will also influence, but generally, if advancement and request remain solid, Eli Lilly’s future looks promising.
| Market Cap | $841Billion |
| Enterprise Value | $844.27 Billion |
| 52 Week High/Low | $972 and $711 |
| Stock P/E | 90.88 |
| Book Value | $15.83 |
| Dividend Yield | 0.64% |
| ROCE | 14.49 |
| ROE | 16.25 |
| Face Value | $961 |
| Price to Book Value | $15.83 |
| EPS | 52.7 |
| Debt | 0.41 |
| Promoters Holding | 50.23% |
Financial Performance of Eli Lilly Stock
Eli Lilly stock is presently trading at $844.27 standard exchange, which is 3.19% lower than its previous close price. The organization has reported a slight slowdown in the growth of its weight drugs, Monjaro, and Zepbound deals, due to which the stock witnessed a decline. However, the organization’s income figure for 2025 is between $58 billion to $61 billion, which shows growth of up to 32%. Experts believe Eli Lilly stock could reach up to $1,140 in 2025, which is a potential gain of up to 35%.
| Revenue | $61Billion |
| Net Income | $58 Billion |
| Diluted EPS | $22.50 |
| Net Profit Margin | $140 |
Eli Lilly Stock Share Holding Pattern
Eli Lilly’s stock price in 2025 could be between $776.17 and $1,153.27. The shareholding design of the organization is as follows:
This information is as of February 2025.
Eli Lilly Stock Forecast Target 2025
| HOLDING | Sep 2024 |
| Promotets Holding | 50.23% |
| FllHolding | 10.33% |
| Dll Holding | 14.68% |
| Public Holding | 35.86 |
Eli Lilly Stock Forecast Target 2025
Eli Lilly stock is expected to see solid growth by 2025, expected target of $650-$700, driven by areas of strength for buy and market predominance.
| Year | Price Target |
| 2025 | $650-$700 |
Eli Lilly Stock Forecast Target 2026
Eli Lilly’s stock gauge for 2026 looks positive, with potential development-driven areas of strength for by pipeline and market extension. The target cost could reach $800+ by 2026.
| Year | Price Target |
| 2026 | $800+ |
Eli Lilly Stock Forecast Target 2027
Eli Lilly stock can show solid growth till 2027, the expected target can be around $800-900 driven by inventory products.
| Year | Price Target |
| 2027 | $800+$900 |
Eli Lilly Stock Forecast Target 2028
Eli Lilly stock’s target till 2028 seems hopeful, with expected development-driven areas of strength for pipeline and worldwide interest. The target can be approx $700-800.
| Year | Price Target |
| 2028 | $700-$800 |
Eli Lilly Stock Forecast Target 2029
The target price of Eli Lilly stock by 2029 could be between $2,182 and $2,749, which is 26% to 59% above today’s price.
| Year | Price Target |
| 2028 | $2,749 |
Eli Lilly Stock Forecast Target 2030
Eli Lilly stock targets solid growth through 2030, with costs expected to increase significantly driven by the organization’s advancements and market strength.
| Year | Price Target |
| 2030 | Not Available |
Eli Lilly Stock Forecast Target 2035
Eli Lilly’s stock target can be bullish by 2035, with expected development in the medical care area and advancements, the cost can go up to $1500+.
| Year | Price Target |
| 2035 | $1500+ |
Eli Lilly Stock Forecast Target 2040
Eli Lilly’s stock projection for 2040 is hopeful, with potential development-driven areas of strength for pipeline and market extension. Target price could reach $1,500+.
| Year | Pice Target |
| 2040 | $1,500+ |
Factors Influencing Stock Price Target
Eli Lilly’s stock estimate may be positive for 2025 because of the solid medicine pipeline and market extension. Factors such as income development, Research and development headways, administrative endorsements, and worldwide medical care requests will impact share cost. Target may have up potential in 2025.
Future Growth Prospects of the Eli Lilly Stock Forecast 2025?
There is a positive slack for the future development possibilities of Eli Lilly stock for 2025. The organization’s solid pipeline, imaginative therapies, and learning experiences in regions such as diabetes and other diseases can have good potential to gain good share cost. Experts are hopeful.
Final Thought
Eli Lilly Stock Forecast 2025 looks encouraging because of the solid medication pipeline and development in diabetes, malignant growth, and Alzheimer’s medicines. Market investigators anticipate consistent income increments and the potential stock price rises, however financial backers ought to look for market instability and administrative changes.
FAQs
What is the estimate of Eli Lilly Stock 2025?
Eli Lilly stock can see development till 2025 because of solid item pipeline and medical services interest.
Is Eli Lilly stock safe?
The organization is stable, but market instability can influence it.
What can be the target price of Eli Lilly till 2025?
Examiners gauge can be $600+.
What is the profit strategy of Eli Lilly?
The organization routinely pays a profit, there is potential for development also.
How will the competition influence Eli Lilly?
There can be solid competition, but imaginative medications will give a strategic advantage to the organization.
Rea Also : Joby Stock Price Prediction 2025 – 2030 Future Outlook & Growth Forecast
Disclaimer
This is just an examination for Eli Lilly Stock Forecast 2025, which is based on market patterns and research standards. This is not a monetary advice. There are risks in financial exchange, and every financial backer should do its own research and consult its monetary counsel. Is not capable of precision or future execution of this figure. Make contributing choices on your own tact.